Adrianna Janell Browne, MD
Dermatology · Orinda
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 12
- 2 carriers
- Office
- 1
- Since medical school
- 19 years
- Johns Hopkins University School of Medicine, 2007
Offices
1 location
Looking this up.
Plans that list them
12 plans · 2 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Browne’s office at (925) 317-1180 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
12 of 12 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Imperial Courage Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Dynamic Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Senior Value (HMO C-SNP) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
California Medical Board record
Licence A116404 · Current
Licensed to practise in California · since 2011 · expires 2027-04-30 · Johns Hopkins University School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
School, training and certification
What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.
Specialty certification
- American Board of Dermatology - Dermatology
Original Medicare doctor bills
$20,196
Medicare paid this office $20,196 for 78 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 40 | $6,287 | $105 |
| Short return visit (20+ min) | 33 | $3,387 | $74 |
| Destruction of precancer skin growth, 1 growth | 45 | $3,226 | $54 |
| Biopsy of related skin growth, first growth | 14 | $1,447 | $90 |
| New patient visit (45+ min) | 11 | $1,343 | $122 |
See all 7 services
| Return visit (30+ min) | 40 | $6,287 | $105 |
| Short return visit (20+ min) | 33 | $3,387 | $74 |
| Destruction of precancer skin growth, 1 growth | 45 | $3,226 | $54 |
| Biopsy of related skin growth, first growth | 14 | $1,447 | $90 |
| New patient visit (45+ min) | 11 | $1,343 | $122 |
| New patient visit (30+ min) | 12 | $1,209 | $101 |
| Destruction of precancer skin growth, 2-14 growths | 31 | $979 | $7 |
Procedures Medicare counted
| Removal of skin lesions | 124 | More than 77% of doctors who do this |
| Skin biopsy | 29 | More than 65% of doctors who do this |
Procedures year by year
| Procedure | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Destruction of precancer skin growth, 2-14 growths | 778 | 85 | 49 | 122 | 118 | 150 |
| Destruction of precancer skin growth, 1 growth | 241 | 28 | 21 | 50 | 42 | 60 |
| Biopsy of related skin growth, first growth | 77 | 12 | 12 | 17 | 17 | 16 |
| Destruction of skin growth, 1-14 growths | 74 | 16 | – | 11 | – | – |
| Destruction of precancer skin growth, 15 or more growths | 27 | – | – | – | – | – |
| Biopsy of related skin growth, each additional growth | 27 | – | – | – | – | – |
Times billed to Original Medicare each year. A blank year means fewer than 11 people had it, or none: Medicare does not publish smaller counts. Medicare Advantage patients are not included.
Who their Medicare patients are
78 Original Medicare patients in 2024. Average age 76 · Women 68% · Also on Medicaid 0% · Health risk score 0.79. At or below the middle of the specialty; the typical dermatology clinician is at 1.01.
Conditions among them: High blood pressure 47% · Chronic kidney disease 21% · Cancer 19% · Depression 15%.
The office billed $32,943, Medicare allowed $27,687 and paid $20,196; for 389 services of 16 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 78 | 389 | 76 | 0.79 | $32,943 | $20,196 |
| 2023 | 69 | 321 | 74 | 0.63 | $28,560 | $17,945 |
| 2022 | 74 | 382 | 74 | 0.63 | $36,549 | $21,081 |
| 2021 | 60 | 202 | 74 | 0.64 | $21,888 | $12,623 |
| 2020 | 89 | 256 | 74 | 0.97 | $36,600 | $10,231 |
| 2019 | 372 | 5,073 | 74 | 0.88 | $171,095 | $106,786 |
| 2018 | 328 | 4,160 | 74 | 0.95 | $125,873 | $80,087 |
| 2017 | 292 | 1,397 | 73 | 0.94 | $110,460 | $75,927 |
| 2016 | 33 | 104 | 76 | 0.95 | $7,278 | $5,252 |
| 2015 | 290 | 1,550 | 75 | 0.94 | $179,926 | $69,211 |
| 2014 | 263 | 1,166 | 73 | 0.96 | $118,858 | $46,693 |
| 2013 | 332 | 1,800 | 73 | 1.08 | $185,198 | $73,244 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 6 services
| Return visit (30+ min) | 42 | $7,336 | $108 |
| Destruction of precancer skin growth, 1 growth | 28 | $2,140 | $51 |
| Short return visit (20+ min) | 22 | $2,014 | $69 |
| Biopsy of related skin growth, first growth | 13 | $1,588 | $93 |
| New patient visit (30+ min) | 14 | $1,296 | $93 |
| Destruction of precancer skin growth, 2-14 growths | 24 | $744 | $6 |
2022: 8 services
| Return visit (30+ min) | 34 | $5,149 | $90 |
| Short return visit (20+ min) | 33 | $3,959 | $71 |
| Destruction of precancer skin growth, 1 growth | 34 | $2,690 | $54 |
| New patient visit (45+ min) | 16 | $1,775 | $111 |
| Biopsy of related skin growth, first growth | 16 | $1,422 | $84 |
| Destruction of skin growth, 1-14 growths | 11 | $1,154 | $105 |
| New patient visit (30+ min) | 12 | $904 | $75 |
| Destruction of precancer skin growth, 2-14 growths | 27 | $803 | $7 |
2021: 6 services
| Return visit (30+ min) | 19 | $2,634 | $88 |
| Short return visit (20+ min) | 26 | $2,182 | $64 |
| New patient visit (45+ min) | 11 | $1,599 | $145 |
| Destruction of precancer skin growth, 1 growth | 20 | $1,084 | $52 |
| Biopsy of related skin growth, first growth | 11 | $1,021 | $85 |
| Destruction of precancer skin growth, 2-14 growths | 11 | $315 | $6 |
2020: 6 services
| Return visit (30+ min) | 48 | $2,555 | $48 |
| Short return visit (20+ min) | 36 | $1,943 | $47 |
| Destruction of skin growth, 1-14 growths | 16 | $1,368 | $86 |
| Destruction of precancer skin growth, 1 growth | 26 | $1,121 | $40 |
| Biopsy of related skin growth, first growth | 11 | $1,013 | $84 |
| Destruction of precancer skin growth, 2-14 growths | 18 | $526 | $6 |
2019: 13 services
| Return visit (30+ min) | 215 | $31,849 | $95 |
| Short return visit (20+ min) | 170 | $13,080 | $60 |
| Destruction of precancer skin growth, 1 growth | 168 | $12,745 | $53 |
| Destruction of skin growth, 1-14 growths | 67 | $7,592 | $103 |
| Biopsy of related skin growth, first growth | 65 | $6,796 | $88 |
| New patient visit (30+ min) | 73 | $5,849 | $80 |
| Destruction of precancer skin growth, 2-14 growths | 128 | $4,292 | $6 |
| Destruction of precancer skin growth, 15 or more growths | 23 | $3,870 | $143 |
| New patient visit (15+ min) | 61 | $3,409 | $56 |
| Aminolevulinic acid hcl for topical administration, 10% gel, 10 mg | 12 | $3,242 | None |
| Application of light to destroy precancer skin growth | 12 | $1,494 | $100 |
| Biopsy of related skin growth, each additional growth | 14 | $1,446 | $54 |
| Short return visit | 12 | $659 | $39 |
2018: 11 services
| Return visit (30+ min) | 152 | $19,805 | $85 |
| Short return visit (20+ min) | 138 | $9,975 | $55 |
| Biopsy of single growth of skin and/or tissue | 82 | $8,726 | $90 |
| Destruction of precancer skin growth, 1 growth | 112 | $7,344 | $47 |
| Destruction of precancer skin growth, 15 or more growths | 27 | $4,815 | $127 |
| New patient visit (30+ min) | 66 | $4,601 | $70 |
| Destruction of skin growth, 1-14 growths | 39 | $4,481 | $97 |
| New patient visit (15+ min) | 57 | $2,930 | $51 |
| Destruction of precancer skin growth, 2-14 growths | 91 | $2,669 | $5 |
| Biopsy of each additional growth of skin and/or tissue | 26 | $1,298 | $29 |
| Short return visit | 24 | $1,058 | $39 |
2017: 12 services
| Return visit (30+ min) | 117 | $13,098 | $90 |
| Short return visit (20+ min) | 141 | $11,969 | $60 |
| Destruction of precancer skin growth, 1 growth | 99 | $6,907 | $54 |
| Biopsy of single growth of skin and/or tissue | 61 | $5,890 | $91 |
| New patient visit (30+ min) | 67 | $5,617 | $84 |
| Destruction of skin growth, 1-14 growths | 41 | $5,122 | $102 |
| Intermediate repair of wound of scalp, underarms, trunk, arms, or legs, 2.6-7.5 cm | 14 | $3,890 | $259 |
| New patient visit (15+ min) | 50 | $3,183 | $64 |
| Destruction of precancer skin growth, 15 or more growths | 18 | $3,175 | $138 |
| Destruction of precancer skin growth, 2-14 growths | 82 | $2,815 | $5 |
| Application of light to destroy precancer skin growth | 11 | $1,939 | $129 |
| Biopsy of each additional growth of skin and/or tissue | 12 | $447 | $30 |
2016: 1 service
| Short return visit (20+ min) | 16 | $1,048 | $66 |
2015: 10 services
| Return visit (30+ min) | 131 | $12,549 | $85 |
| Short return visit (20+ min) | 130 | $9,883 | $61 |
| Biopsy of single growth of skin and/or tissue | 89 | $8,188 | $85 |
| Destruction of precancer skin growth, 1 growth | 138 | $7,633 | $46 |
| Destruction of skin growth, 1-14 growths | 52 | $5,771 | $98 |
| Destruction of precancer skin growth, 15 or more growths | 30 | $4,166 | $130 |
| Destruction of precancer skin growth, 2-14 growths | 112 | $3,474 | $5 |
| New patient visit (30+ min) | 28 | $2,406 | $86 |
| New patient visit (15+ min) | 41 | $2,142 | $52 |
| Biopsy of each additional growth of skin and/or tissue | 35 | $1,373 | $28 |
2014: 12 services
| Short return visit (20+ min) | 122 | $8,154 | $50 |
| Return visit (30+ min) | 93 | $7,023 | $68 |
| Biopsy of single growth of skin and/or tissue | 75 | $5,793 | $76 |
| Destruction of precancer skin growth, 1 growth | 100 | $4,867 | $42 |
| Destruction of skin growth, 1-14 growths | 45 | $4,059 | $85 |
| Destruction of precancer skin growth, 2-14 growths | 70 | $3,333 | $8 |
| New patient visit (30+ min) | 46 | $2,711 | $59 |
| Destruction of precancer skin growth, 15 or more growths | 14 | $1,870 | $110 |
| New patient visit (15+ min) | 43 | $1,863 | $43 |
| Biopsy of each additional growth of skin and/or tissue | 22 | $782 | $26 |
| Injection into skin growth, 1-7 growths | 14 | $485 | $30 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 15 | $32 | None |
2013: 11 services
| Return visit (30+ min) | 135 | $12,815 | $76 |
| Short return visit (20+ min) | 128 | $9,725 | $53 |
| Biopsy of single growth of skin and/or tissue | 116 | $9,060 | $72 |
| Destruction of precancer skin growth, 1 growth | 127 | $8,041 | $47 |
| Destruction of skin growth, 1-14 growths | 73 | $7,252 | $85 |
| New patient visit (30+ min) | 100 | $7,047 | $70 |
| Destruction of precancer skin growth, 15 or more growths | 29 | $4,628 | $132 |
| Destruction of precancer skin growth, 2-14 growths | 102 | $3,645 | $5 |
| New patient visit (15+ min) | 75 | $3,317 | $44 |
| Biopsy of each additional growth of skin and/or tissue | 29 | $952 | $25 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 17 | $44 | None |
Drugs they prescribed that Part D paid
$6,833
Pharmacies billed $6,833 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 194) in 2024. At or below the middle of the specialty; the typical dermatology clinician is at 0%.
188 generic and fewer than 11 brand-name prescriptions · $6,833 in drug cost · 14 antibiotic prescriptions.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Fluorouracil | 17 | $1,056 | $62 |
| Clobetasol Propionate | 17 | $718 | $42 |
| Hydrocortisone | 26 | $162 | $6 |
| Mupirocin | 14 | $135 | $10 |
| Triamcinolone Acetonide | 12 | $93 | $8 |
Year by year
| 2024 | 194 | 61 | 0% (0) | None | $6,833 |
| 2023 | 192 | 63 | 0% (0) | None | $9,169 |
| 2022 | 209 | 83 | 0% (0) | 0% | $9,452 |
| 2021 | 371 | 170 | 0% (0) | None | $32,552 |
| 2020 | 309 | 153 | 0% (0) | 8% | $78,188 |
| 2019 | 473 | 194 | 0% (0) | 8% | $140,638 |
| 2018 | 341 | 137 | 0% (0) | 7% | $85,891 |
| 2017 | 283 | 124 | 0% (0) | None | $125,988 |
| 2016 | 157 | 88 | None | 10% | $11,926 |
| 2015 | 256 | 136 | None | 13% | $25,775 |
| 2014 | 338 | 124 | 0% (0) | None | $31,815 |
| 2013 | 337 | 127 | 0% (0) | None | $29,622 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 6 drugs
| Fluorouracil | 17 | $1,299 | $76 |
| Hydroxychloroquine Sulfate | 16 | $625 | $39 |
| Dutasteride | 17 | $400 | $24 |
| Clobetasol Propionate | 17 | $359 | $21 |
| Nystatin | 12 | $296 | $25 |
| Hydrocortisone | 19 | $117 | $6 |
2022: 6 drugs
| Fluorouracil | 30 | $2,637 | $88 |
| Clobetasol Propionate | 17 | $916 | $54 |
| Hydroxychloroquine Sulfate | 11 | $651 | $59 |
| Triamcinolone Acetonide | 16 | $202 | $13 |
| Mupirocin | 13 | $136 | $10 |
| Hydrocortisone | 20 | $115 | $6 |
2021: 9 drugs
| Fluorouracil | 80 | $5,987 | $75 |
| Tacrolimus | 14 | $2,232 | $159 |
| Clobetasol Propionate | 39 | $2,027 | $52 |
| Fluocinonide | 28 | $1,833 | $65 |
| Ketoconazole | 25 | $489 | $20 |
| Valacyclovir | 11 | $324 | $29 |
| Hydrocortisone | 27 | $258 | $10 |
| Triamcinolone Acetonide | 16 | $220 | $14 |
| Mupirocin | 14 | $132 | $9 |
2020: 8 drugs
| Fluorouracil | 66 | $4,753 | $72 |
| Clobetasol Propionate | 21 | $1,420 | $68 |
| Fluocinonide | 14 | $790 | $56 |
| Mupirocin | 26 | $398 | $15 |
| Econazole Nitrate | 11 | $347 | $32 |
| Ketoconazole | 19 | $301 | $16 |
| Triamcinolone Acetonide | 19 | $216 | $11 |
| Hydrocortisone | 14 | $167 | $12 |
2019: 14 drugs
| Fluorouracil | 46 | $5,400 | $117 |
| Clobetasol Propionate | 22 | $1,818 | $83 |
| Econazole Nitrate | 32 | $1,420 | $44 |
| Fluocinonide | 21 | $1,279 | $61 |
| Betamethasone Dipropionate | 16 | $1,264 | $79 |
| Ketoconazole | 39 | $1,078 | $28 |
| Triamcinolone Acetonide | 59 | $610 | $10 |
| Hydroxychloroquine Sulfate | 13 | $519 | $40 |
| Hydroxyzine | 12 | $381 | $32 |
| Doxycycline Hyclate | 11 | $227 | $21 |
| Mupirocin | 24 | $214 | $9 |
| Hydrocortisone | 39 | $176 | $5 |
| Valacyclovir | 11 | $170 | $15 |
| Levocetirizine Dihydrochloride | 13 | $140 | $11 |
2018: 8 drugs
| Clobetasol Propionate | 34 | $3,833 | $113 |
| Fluorouracil | 19 | $2,248 | $118 |
| Econazole Nitrate | 26 | $2,112 | $81 |
| Ketoconazole | 25 | $849 | $34 |
| Triamcinolone Acetonide | 43 | $547 | $13 |
| Hydroxyzine | 17 | $459 | $27 |
| Mupirocin | 16 | $146 | $9 |
| Hydrocortisone | 24 | $140 | $6 |
2017: 9 drugs
| Econazole Nitrate | 23 | $4,419 | $192 |
| Clobetasol Propionate | 31 | $3,621 | $117 |
| Fluorouracil | 11 | $1,306 | $119 |
| Ketoconazole | 28 | $1,229 | $44 |
| Doxycycline Hyclate | 18 | $883 | $49 |
| Fluocinonide | 11 | $668 | $61 |
| Triamcinolone Acetonide | 23 | $270 | $12 |
| Mupirocin | 24 | $197 | $8 |
| Hydrocortisone | 23 | $139 | $6 |
2016: 6 drugs
| Clobetasol Propionate | 15 | $1,735 | $116 |
| Fluorouracil | 11 | $1,349 | $123 |
| Econazole Nitrate | 11 | $1,092 | $99 |
| Triamcinolone Acetonide | 20 | $354 | $18 |
| Hydroxyzine | 14 | $209 | $15 |
| Mupirocin | 17 | $162 | $10 |
2015: 10 drugs
| Econazole Nitrate | 22 | $4,894 | $222 |
| Fluorouracil | 32 | $4,034 | $126 |
| Clobetasol Propionate | 26 | $3,602 | $139 |
| Fluocinolone Acetonide | 12 | $2,134 | $178 |
| Desonide | 13 | $1,586 | $122 |
| Triamcinolone Acetonide | 32 | $606 | $19 |
| Valacyclovir | 11 | $459 | $42 |
| Hydroxyzine | 13 | $254 | $20 |
| Mupirocin | 16 | $253 | $16 |
| Doxycycline Monohydrate | 13 | $218 | $17 |
2014: 10 drugs
| Fluorouracil | 23 | $3,957 | $172 |
| Desonide | 21 | $3,018 | $144 |
| Doxycycline Hyclate | 14 | $1,462 | $104 |
| Clobetasol Propionate | 26 | $1,305 | $50 |
| Econazole Nitrate | 25 | $1,189 | $48 |
| Triamcinolone Acetonide | 47 | $788 | $17 |
| Valacyclovir | 11 | $313 | $28 |
| Ketoconazole | 17 | $272 | $16 |
| Hydroxychloroquine Sulfate | 24 | $179 | $7 |
| Mupirocin | 13 | $159 | $12 |
2013: 5 drugs
| Fluorouracil | 28 | $5,087 | $182 |
| Desonide | 28 | $4,594 | $164 |
| Clobetasol Propionate | 34 | $1,307 | $38 |
| Triamcinolone Acetonide | 36 | $768 | $21 |
| Hydroxychloroquine Sulfate | 26 | $268 | $10 |
Money from drug and device companies
$714 in 2025
| 2025 | 10 | 20 | None | $714 |
| 2024 | 12 | 34 | None | $1,001 |
| 2023 | 11 | 28 | None | $1,043 |
| 2022 | 10 | 38 | None | $1,250 |
| 2021 | 9 | 30 | None | $883 |
| 2020 | 4 | 8 | None | $259 |
| 2019 | 8 | 21 | None | $467 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Revance Therapeutics | Daxxify | $347 | 6 payments
|
| Pfizer | Cibinqo | $127 | 5 payments
|
| Incyte | Opzelura | $60 | 2 payments
|
| Regeneron Healthcare Solutions | Dupixent | $40 | 1 payment
|
| Ucb | Bimzelx | $26 | 1 payment
|
| Novartis Pharmaceuticals | Rhapsido | $25 | 1 payment
|
See all 20 published payments
| Novartis Pharmaceuticals | Meals · 2025-12-05 | Rhapsido | $25 |
| Galderma Laboratories L.P. | Meals · 2025-12-02 | None | $24 |
| Revance Therapeutics | Meals · 2025-10-29 | Daxxify | $40 |
| Regeneron Healthcare Solutions | Meals · 2025-10-16 | Dupixent | $40 |
| Ucb | Meals · 2025-10-14 | Bimzelx | $26 |
| Ortho Dermatologics a division of Bausch Health US | Meals · 2025-09-23 | Jublia | $20 |
| Incyte | Meals · 2025-09-23 | Opzelura | $30 |
| Pfizer | Meals · 2025-09-16 | Cibinqo | $28 |
| Revance Therapeutics | Meals · 2025-09-03 | Daxxify | $44 |
| Arcutis Biotherapeutics | Meals · 2025-08-15 | Zoryve | $24 |
| Revance Therapeutics | Meals · 2025-07-07 | Daxxify | $62 |
| Pfizer | Meals · 2025-07-03 | Cibinqo | $16 |
| Revance Therapeutics | Meals · 2025-06-25 | Daxxify | $100 |
| Revance Therapeutics | Meals · 2025-06-04 | Daxxify | $46 |
| Pfizer | Meals · 2025-05-07 | Cibinqo | $27 |
| Pfizer | Meals · 2025-04-28 | Cibinqo | $26 |
| Incyte | Meals · 2025-02-11 | Opzelura | $30 |
| Revance Therapeutics | Meals · 2025-01-31 | Daxxify | $54 |
| Organon | Meals · 2025-01-15 | Vtama | $23 |
| Pfizer | Meals · 2025-01-08 | Cibinqo | $29 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $1,001
| Pfizer | Cibinqo | $199 | 10 payments
|
| Incyte | Opzelura | $111 | 4 payments
|
| Revance Therapeutics | Daxxify | $109 | 2 payments
|
| Novartis Pharmaceuticals | Cosentyx | $100 | 3 payments
|
| Ucb | Bimzelx | $93 | 2 payments
|
| Lilly USA | Taltz | $92 | 3 payments
|
| Abbvie | Rinvoq | $88 | 4 payments
|
| Galderma Laboratories L.P. | Dysport | $61 | 1 payment
|
| Janssen Biotech | Tremfya | $59 | 2 payments
|
| Regeneron Healthcare Solutions | Dupixent | $39 | 1 payment
|
| Biofrontera | Ameluz | $29 | 1 payment
|
| Arcutis Biotherapeutics | Zoryve | $21 | 1 payment
|
2023: $1,043
| Genzyme | Dupixent | $240 | 4 payments
|
| Incyte | Opzelura | $178 | 3 payments
|
| Janssen Biotech | Tremfya | $171 | 6 payments
|
| Lilly USA | Taltz | $128 | 4 payments
|
| Regeneron Healthcare Solutions | Dupixent | $70 | 2 payments
|
| LEO Pharma | Adbry | $61 | 3 payments
|
| Galderma Laboratories L.P. | None | $59 | 1 payment
|
| Pfizer | Cibinqo | $49 | 2 payments
|
| Biofrontera | Ameluz | $34 | 1 payment
|
| AbbVie | Skyrizi | $29 | 1 payment
|
| Ortho Dermatologics a division of Bausch Health US | Jublia | $23 | 1 payment
|
2022: $1,250
| Genzyme | Dupixent | $229 | 4 payments
|
| Janssen Biotech | Remicade | $224 | 12 payments
|
| Regeneron Healthcare Solutions | Dupixent | $205 | 7 payments
|
| Lilly USA | Taltz | $155 | 5 payments
|
| Abbvie | Rinvoq | $134 | 1 payment
|
| LEO Pharma | Adbry | $103 | 2 payments
|
| Novartis Pharmaceuticals | Cosentyx | $85 | 3 payments
|
| Allergan | Botox | $48 | 2 payments
|
| Merz North America | Xeomin | $42 | 1 payment
|
| Galderma Laboratories L.P. | None | $25 | 1 payment
|
2021: $883
| AbbVie | Skyrizi | $164 | 2 payments
|
| LEO Pharma | Enstilar | $144 | 6 payments
|
| Regeneron Healthcare Solutions | Dupixent | $137 | 4 payments
|
| Allergan | Botox | $134 | 5 payments
|
| Genzyme | Dupixent | $120 | 6 payments
|
| Pfizer | Eucrisa | $55 | 2 payments
|
| Lilly USA | Taltz | $54 | 2 payments
|
| Novartis Pharmaceuticals | Cosentyx | $50 | 2 payments
|
| Incyte | Opzelura | $25 | 1 payment
|
2020: $259
| Genzyme | Dupixent | $133 | 2 payments
|
| Galderma Laboratories L.P. | Aklief | $64 | 3 payments
|
| Pfizer | Eucrisa | $36 | 2 payments
|
| Allergan | None | $26 | 1 payment
|
2019: $467
| Pfizer | Eucrisa | $136 | 11 payments
|
| Genzyme | Dupixent | $134 | 2 payments
|
| Galderma Laboratories L.P. | Epiduo Forte | $45 | 2 payments
|
| AbbVie | Skyrizi | $44 | 2 payments
|
| Janssen Biotech | Tremfya | $34 | 1 payment
|
| LEO Pharma | Enstilar | $32 | 1 payment
|
| Biofrontera | Ameluz | $25 | 1 payment
|
| Lilly USA | Taltz | $16 | 1 payment
|
Professional record
- NPI
- 1699968305
- Licence
- CA A116404, MD P21900, TX P3009California A116404: Current · expires 2027-04-30
- Trained
- Johns Hopkins University School of Medicine, 2007 · 19 years ago
- Gender
- Female
More record details
- Sole proprietor
- Yes
- Taxonomy
- Federal specialty code 207N00000X (207N00000X); Federal specialty code 207NI0002X (207NI0002X); Internal medicine (207R00000X)
- Mailing address
- 8 Camino Encinas Ste 115, Orinda, CA, 94563
- NPI first listed
- 2007-08-26
- NPI last updated
- 2026-04-24
- NPI record certified
- 2026-04-24
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 8 Camino Encinas, Orinda, CA, 94563